Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Moderna

Generate pivotal study data for MMA therapeutic mRNA-3705

Delivered by the deadline

AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.

Announced
12 Sep 2024
Due
31 Dec 2024
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“The Company is on track to begin generating pivotal study data by the end of 2024.”
  • SourceModerna Form 8-K press release, 2024-09-12
  • FilingSEC filing index
  • Deadline as statedby the end of 2024
  • Deadline used31 Dec 2024, the last day of the stated period
  • TypeProject
  • Permanent referenceKI-C-2024-MRNA-006230
    Cite as https://keptindex.org/c/KI-C-2024-MRNA-006230/ — this address never changes.

What we found

Evidence strength A What the grades mean

Later 10-K and 8-K filings state Moderna began generating registrational trial data in 2024, within the stated period.

  • A
    Moderna 8-K filed 2025-02-14 Regulatory filing · published 14 Feb 2025 · retrieved 10 Oct 2026 · kept permanently by the SEC · fingerprint c696a3eeff10
    “The Company began generating registrational trial data in 2024.” ✓ confirmed on the page
  • A
    Moderna 10-K filed 2025-02-21 Regulatory filing · published 21 Feb 2025 · retrieved 10 Oct 2026 · kept permanently by the SEC · fingerprint e2b7c6073e1a
    “We began generating registrational trial data in the Phase 1/2 study in 2024.” ✓ confirmed on the page

Market reaction: the shares moved +11.9% against the S&P 500 over the three sessions around the disclosure (13 Feb 2025 to 19 Feb 2025). What this measures

Checked 10 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Clinical readout late
Indicative materiality
High rules
Action
Generate
Deliverable
Pivotal study data for methylmalonic acidemia therapeutic mRNA-3705
Language
Firm (“will”, “on track to”)
In the company’s control
Medium
Specificity
Medium

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
  3. Second check: disagreesGemini (Google) re-read the evidence blind and read it as “Not met”.
  4. Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.

Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works

Are you Moderna? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2024-MRNA-006230 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.